No Data
Shanghai Henlius Begins Key Breast Cancer Drug Trial
HENLIUS (02696.HK): The international multicenter phase 3 clinical study comparing HLX78 (lasofoxifene tablets) in combination with abemaciclib to fulvestrant in combination with abemaciclib for locally advanced or metastatic breast cancer has completed t
On December 24, Glonghui reported that HENLIUS (02696.HK) announced a recent comparison of HLX78 (lasofoxifene) combined with Abemaciclib and Fulvestrant in the treatment of premenopausal/postmenopausal women and men with locally advanced hormone receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), carrying estrogen receptor 1 (ESR1) mutations who have previously received aromatase inhibitors (AI) combined with Palbociclib or Ribociclib as the first hormonal therapy regimen for metastatic disease.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
HENLIUS disclosed the latest progress on privatization: there are currently no Other listing plans.
① FOSUN PHARMA and HENLIUS jointly released a comprehensive document for the absorption and merger of HENLIUS, and there are currently no plans to be listed on other Exchanges. ② After privatization is completed, HENLIUS will continue to engage in its current main Business, and it will retain the existing employees and the current hiring and recruitment practices will not be affected.
Shanghai Henlius Biotech Moves Toward Privatization
Shanghai Henlius Biotech to Vote on Major Merger
No Data
